First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Rapidly Developed SARS-CoV-2 Therapeutic Antibody, AOD01, in Healthy Adults.
Prativadibhayankaram VS, Lee LS, Lye D, Xiaoying X, Nellore R, Pendharkar V, Hentze H, Guan S, Ayers BJ, Seah SGK, Chye H, Talib NSN, Kaliaperumal N, Ong WY, Wong ZX, Au VB, Alok A, Connolly JE, Boyd-Kirkup JD, Ingram PJ, Hanson BJ, Ethirajulu K, O'Connell D, Chan CEZ.
Prativadibhayankaram VS, et al.
Infect Dis Ther. 2022 Oct;11(5):1999-2015. doi: 10.1007/s40121-022-00681-1. Epub 2022 Sep 4.
Infect Dis Ther. 2022.
PMID: 36058990
Free PMC article.